Innovative and Targeted Cancer Therapies: Key technologies, new applications and leading players–Aarkstore Enterprise

Aarkstore announce a new report  ” Innovative and Targeted Cancer Therapies: Key technologies, new applications and leading players ” through its vast collection of market research report.

Portfolio of healthcare management reports are designed to help you make well informed and timely business decisions. We understand the problems facing today’s pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions. The strength of our healthcare research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Business Insights reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors’ leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry. Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight.

Some key findings from this report…

The global market for cancer innovatives has more than trebled in size over the last four years, achieving a compound annual growth rate (CAGR) of 33.1% between 2003 and 2006.

Monoclonal antibodies comprised four of the top ten leading cancer innovatives in 2006, supplemented by novel chemotherapeutics, hormonals and targeted therapies.

Ten ‘blockbuster’ drugs are likely to emerge in cancer therapy over the next decade as recent and impending scientific breakthroughs continue to enhance treatment options.

Mononclonal antibodies will experience a surge in market growth after label extensions into new treatment settings and indications.

Genentech and Roche continue to command a substantial proportion of the cancer innovatives market, generating almost 50% of all sales in 2006.

Innovative and Targeted Cancer Therapies

The highly dynamic cancer market is creating a new age of discovery and innovation driven by molecular biology, oncogenomics and new methods in cell biology. Resultantly, cancer innovatives are not only the fastest growing segment within the cancer market, but the key drivers of sales growth across the pharmaceutical market as a whole. These innovations will result in high value opportunities to develop newer and more effective therapies, ensuring companies can effectively respond to the increasing prevalence of cancer. Innovative and Targeted Cancer Therapies provides a detailed insight into both cancer therapeutics and diagnostics, to provide a clear vision of how the cancer market will develop over the next five years. It also identifies key alliance and partnering opportunities, highlighting companies with specialised capabilities in the discovery and the characterization of next-generation drug targets. Use this report to understand how the cancer market is developing, identify areas of unmet medical need and align your product pipeline to achieve clinical and commercial success.

Top five reasons to order your copy today

Fully understand and assess your organisation’s situation within the evolving market environment, through the identification of innovative cancer classes, products and partnering opportunities.

Exploit under served therapy sectors within the Oncology market more effectively by evaluating the most significant areas of under provision, as identified by this report

Secure the long term success of your portfolio by examining the strategies that can effectively promote new product development and the lifecycle management of innovatives.

Gain detailed competitive intelligence and enhance your strategic outlook by benchmarking the successful strategies employed by the leading companies within the industry.

Synchronize your future offering with the latest developmental plans and forecasts for innovative cancer products, and with the latest changes in the industry’s pricing and regulatory environment.

Key issues examined in this report…

Identification of a significant number of unmet therapeutic needs. These will form the basis of future treatment developments across a variety of cancer types and treatment settings.

Commercial potential of several rapidly evolving product and technology breakthroughs. Particularly consistent of the market interplay between monoclonal antibodies, targeted therapeutics, novel chemotherapies and hormonal treatments.

Application of existing therapies in new treatment settings and indications bearing increasing importance as a facilitator of wider product lifecycle optimization efforts.

Targeted therapies delivering the most effective treatments for selected cancers. Most notably, these include novel kinase inhibitors and other treatment pathways.

Strategic and market positioning of the leading pharma and biotech companies operating within oncology innovatives.

Your questions answered…

Where are the key supply shortfalls in the cancer market?

What are the most significant areas of new growth within cancer innovatives?

Which emerging product innovations harbour the most significant potential in cancer treatment?

Who are the companies pioneering novel therapies, and what strategies do they employ to integrate successful portfolios?

Which key drug and product classes are set to dominate the cancer innovatives market in 2011?

What important factors can provide a synergistic balance between new product launches and lifecycle management?

For more information, please visit :
http://www.aarkstore.com/reports/Innovative-and-Targeted-Cancer-Therapies-Key-technologies-new-applications-and-leading-players-34836.html
Or email us at press@aarkstore.com or call +919272852585

Special offer till 31th Dec 2009